European companies playing key supporting roles in COVID-19 vaccine manufacturing are working to move production and supply chains closer to their customers to guard against trade restrictions that have interrupted supplies during the pandemic.
If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing deal RemeGen Co Ltd (REGMF) struck last month with Seattle-based Seagen Inc (SGEN) fits the bill. The agreement to co-develop cancer treatments using a RemeGen (REGMF) antibody drug conjugate is regarded as one of the biggest of its kind between a Chinese biotech and a Western firm.
* Siemens Gamesa leads losses after JPMorgan downgrade. * Smiths Group (SMGKF) up on deal to sell medical unit. * ECB expected to trim bond purchases. * Nokian Tyres pulls down auto sector. By Sruthi Shankar and Ambar Warrick.
Japan's benchmark Nikkei share average dipped below the psychologically key 28,000 mark on Friday as tech shares tracked declines on Wall Street overnight, while a continued surge in coronavirus infections dented investor sentiment.
Japan's benchmark Nikkei share average fell below the psychologically key 28,000 mark on Friday as tech shares tracked declines on Wall Street overnight, while a continued surge in coronavirus infections dented investor sentiment.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
Log In Required
